COVID-19 cases dramatically increase in the West, but multiple companies start focusing towards treatments and vaccines. Gilead’s (GILD) Remdesivir is a candidate anti-viral for the treatment of COVID-19 that will have readouts in early April-2020 for their Phase 3 trials. On the vaccine side, Moderna (MRNA) has initiated a Phase 1 trial with their mRNA-1273 vaccine against the SARS-CoV-2 Spike protein. Stay safe out there!
Follow me on twitter @matthewlepoire
Email me at email@example.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt’s opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.
Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech